Literature DB >> 17332323

The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity.

Wan Mui Chan1, Randy Y C Poon.   

Abstract

The transcription factor p53 is one of the most frequently mutated tumor suppressors. Recent progress has unraveled several novel isoforms of p53. Intriguingly, one of the p53 isoform, Deltap53, which lacks part of the DNA binding domain, was reported to be transcriptionally active toward some p53 target genes and is critical for the intra-S phase checkpoint. Here, we show that, in contrast to full-length p53, ectopically expressed Deltap53 neither transactivated the promoters of p21(CIP1/WAF1) or murine double minute-2 (MDM2) nor repressed the cyclin B1 promoter in unstressed H1299 cells. Due to the deletion of a nuclear localization signal, Deltap53 was not imported into the nucleus. Engineering of nuclear localization signals to Deltap53 restored nuclear accumulation. However, the nuclear-targeting Deltap53 remained inactive, indicating that the lack of intrinsic activity of Deltap53 was not simply due to subcellular localization but to its incomplete DNA binding domain. Similar to p53, Deltap53 was subjected to MDM2-mediated ubiquitination/proteolysis. The cytoplasmic localization of Deltap53 correlated with the instability of the protein because forcing Deltap53 into the nucleus increased its stability. Although Deltap53 could form a complex with p53 and stimulated the cytoplasmic retention of p53, it was not a robust inhibitor of p53. Targeting Deltap53 into the nucleus enhanced the dominant-negative activity of Deltap53. These observations underscore the critical role of subcellular localization in the dominant-negative action of p53.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332323     DOI: 10.1158/0008-5472.CAN-06-3602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site.

Authors:  Maria M García-Alai; Henning Tidow; Eviatar Natan; Fiona M Townsley; Dmitry B Veprintsev; Alan R Fersht
Journal:  Protein Sci       Date:  2008-07-11       Impact factor: 6.725

2.  Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Authors:  Wansheng Ji; Na Zhang; Hongmei Zhang; Jingrong Ma; Hua Zhong; Jianxin Jiao; Zhixing Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Specific inhibition of NF-Y subunits triggers different cell proliferation defects.

Authors:  Paolo Benatti; Diletta Dolfini; Alessandra Viganò; Maria Ravo; Alessandro Weisz; Carol Imbriano
Journal:  Nucleic Acids Res       Date:  2011-03-16       Impact factor: 16.971

4.  Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells.

Authors:  Hong-Mei Zhang; Xiao-Guang Sang; Yan-Ze Wang; Can Cui; Li Zhang; Wan-Sheng Ji
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

5.  Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage.

Authors:  Valeriya Solozobova; Alexandra Rolletschek; Christine Blattner
Journal:  BMC Cell Biol       Date:  2009-06-17       Impact factor: 4.241

Review 6.  p53 and its isoforms in cancer.

Authors:  J-C Bourdon
Journal:  Br J Cancer       Date:  2007-07-17       Impact factor: 7.640

7.  Identification of p53 and its isoforms in human breast carcinoma cells.

Authors:  Zorka Milićević; Vladan Bajić; Lada Živković; Jelena Kasapović; Uroš Andjelković; Biljana Spremo-Potparević
Journal:  ScientificWorldJournal       Date:  2014-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.